Lessons from COVID-19 to increase opioid vaccine acceptance.
Roxana Damiescu, Mita Banerjee, Norbert W Paul...
https://pubmed.ncbi.nlm.nih.gov/36123169/Actively Recruiting
Led by New York State Psychiatric Institute · Updated on 2026-04-23
45
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating a new approach to treating opioid use disorder OUD by studying a vaccine targeted against oxycodone, one of the commonly abused prescription opioids. This Phase 1a1b clinical trial aims to assess the safety, immune response, and effectiveness of the OxyGly4-sKLH vaccine in adults aged 18 to 59 years who meet criteria for moderate to severe OUD and are physically dependent on opioids. The study is supported by the New York State Psychiatric Institute and includes participants not currently seeking treatment for their opioid use. The study compares two doses of the OxyGly4-sKLH vaccine low and high dose to a placebo, administered by injection into the deltoid muscle at Weeks 0, 3, 6, and 18. Participants will be randomly assigned to one of these groups in a triple-masked design. The trial includes several phases a screening phase lasting from 6 to 2 weeks before vaccination, an outpatient study visit phase from Week 0 to Week 21, three laboratory sessions at Weeks -1, 7, and 19, and an extended follow-up period from Weeks 23 to 42. During the approximately 42-week participation, individuals will undergo safety monitoring for adverse events, assessments of immune response to the vaccine, and evaluations of the vaccines effect on drug liking after opioid administration. Assessments include blood tests for antibodies, urine drug screens, and subjective effect measures during testing sessions lasting up to 4.5 hours post-dose. Participants must comply with scheduled visits, dosing, and lab tests, with continuous monitoring for safety and immune response throughout the study.
CONDITIONS
Clinical Trials of Multivalent Opioid Vaccine Components
J
Jermaine Jones, PhD
S
Sandra Comer, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
New York State Psychiatric Institute
Lead Sponsor
Clinilabs, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Vaccine | Placebo | Current Standard MOUD |
|---|---|---|---|
| What it is | Opioid vaccine composed of Oxy(Gly)₄ conjugated to keyhole limpet hemocyanin delivered in low or high dose | Placebo version of the Oxy(Gly)₄‑sKLH vaccine without active components | Medications for opioid‑use disorder (MOUD) such as methadone, buprenorphine, and naltrexone |
| Role in trial | Investigational active treatment arm (high‑dose or low‑dose vaccine) | Randomized placebo comparator arm | Current standard pharmacologic treatment outside the trial |
| Primary use | To induce immune response targeting opioid molecules in people with opioid‑use disorder | Control to assess safety and immunogenicity of the investigational vaccine | To reduce opioid craving, withdrawal and risk of overdose in people with opioid‑use disorder |
| How it is given or performed | Given via vaccination in low‑dose or high‑dose formulation according to trial assignment | Matching placebo vaccine administered under same schedule as active vaccine | Medications administered daily or periodically depending on drug: methadone daily, buprenorphine daily or long‑acting injectable, naltrexone monthly injectable or daily oral |
| Evidence status | Preclinical and early clinical evidence for opioid vaccines is limited and mostly preclinical at this time | Placebo does not have effect—used as control only | Strong evidence supports methadone, buprenorphine, and naltrexone in reducing opioid cravings, overdose risk, and mortality |
| Important risks | Safety profile currently uncertain; risks depend on trial outcomes | Placebo expected to carry minimal risk beyond injection discomfort | Methadone, buprenorphine, and naltrexone have known side effects such as sedation, constipation, and nausea depending on drug |
| Important limitations | Currently supported mainly by preclinical data; human efficacy and safety yet to be established | Does not provide therapeutic benefit; serves only as control | Requires daily dosing or clinic visits; patient adherence and access remain challenges |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 21 weeks
Participants receive vaccinations and attend study visits for monitoring and assessments.
Visits at Weeks 0, 3, 6, 7, 18, 19, and 20
Duration - 19 weeks
Participants continue with follow-up visits to monitor safety and immune response after vaccination.
Visits at Weeks 23, 30, 34, 38, and 42
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Roxana Damiescu, Mita Banerjee, Norbert W Paul...
https://pubmed.ncbi.nlm.nih.gov/36123169/New York State Psychiatric Institute
Lead Sponsor
Clinilabs, Inc.
Collaborating Sponsor